triple glp 1 agonist GLP-1 Orals and Multi-Agonists: Advancing Next-Gen Weight Loss Therapies with Humanized Models triple glp 1 agonist The
Description
Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.
Future research should focus on elucidating the complex mechanisms underlying their psychological effects and integrating mental health considerations into therapeutic strategies
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D)
Pfizer has said it expects pills to eventually capture about a third of the obesity drug market, which is predicted to grow to about $130 billion by the end of the decade.
